Drugs / BRIMAPITIDE, C-TERMINAL ACID
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00802425 | Dec 2008 → Jul 2012 | hearing loss disorder | Auris Medical AG | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02809118 | Jun 2016 → Feb 2018 | sudden sensorineural hearing loss | Auris Medical AG | Terminated | No outcome recorded |
| Phase 3 | NCT02561091 | Nov 2015 → Sep 2017 | hearing loss disorder | Auris Medical AG | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRIMAPITIDE, C-TERMINAL ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297348 ↗ |
| Known as | AM-111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02809118 ↗ |
| Known as | D-JNKI-1 | “The active pharmaceutical ingredient of AM-111 is the JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino acids, which acts as a c-Jun N-terminal kinase (JNK) ligand.” NCT02561091 ↗1“The active pharmaceutical ingredient of AM-111 is a JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino acids, which acts as a c-Jun N-terminal kinase (JNK) ligand.” NCT02809118 ↗ |
| Known as | Xg-102 c-terminal acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297348 ↗ |
| Action | Inhibit | “c-Jun N-terminal kinase 3 inhibitor” CHEMBL4297348 ↗1“the JNK inhibitor (D-JNKI-1)” NCT02561091 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297348 ↗ |
| Route | Other | “AM-111 0.4 mg/mL or 0.8 mg/mL or placebo, administered into the affected ear” NCT02809118 ↗ |
| Target | MAPK10 | “c-Jun N-terminal kinase 3 inhibitor” CHEMBL4297348 ↗ |